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GermanyA B S T R A C TBackground: Health states can be valued by those who currently
experience a health state (experienced health states [EHS]) or by
the general public, who value a set of given health states (GHS)
described to them. There has been debate over which method is
more appropriate when making resource allocation decisions.
Objective: This article informs this debate by assessing whether
differences between these methods have an effect on the mean EQ-
5D-3L tariff scores of different patient groups. Methods: The Euro-
pean tariff based on GHS valuations was compared with a German
EHS tariff. Comparison was made in the context of EQ-5D-3L health
states describing a number of diagnosed chronic diseases (stroke,
diabetes, myocardial infarction, and cancer) taken from the Coop-
erative Health Research in the Augsburg Region population sur-
veys. Comparison was made of both the difference in weighting of
the dimensions of the EQ-5D-3L and differences in mean tariffee front matter Copyright & 2014, International S
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ewcastle upon Tyne NE2 4AX, UK.scores for patient groups. Results: Weighting of the dimensions of
the EQ-5D-3L were found to be systematically different. The EHS
tariff gave signiﬁcantly lower mean scores for most, but not all,
patient groups despite tariff scores being lower for 213 of 243 EQ-
5D-3L health states using the GHS tariff. Differences were found to
vary between groups, with the largest change in difference being
5.45 in the multiple stoke group. Conclusions: The two tariffs have
systematic differences that in certain patient groups could drive
the results of an economic evaluation. Therefore, the choice as to
which is used may be critical when making resource allocation
decisions.
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There has been a growing use of measures of health-related
quality of life, such as the EQ-5D-3L [1], over the last quarter
century in many countries [2]. In England, the EQ-5D-3L is the
recommended outcome measure of the National Institute for
Health and Care Excellence [3] and it is being used for patient-
reported outcome measures in the National Health Service [4]. In
Germany, a search using the EuroQol Group Web site returned
106 studies using the EQ-5D-3L [5] as an outcome measure. In
addition, it is written in law that quality of life represents a
patient-relevant outcome measure that should be consideredwhen making reimbursement decisions for pharmaceuticals,
although no speciﬁc instrument is recommended [6].
When using an instrument such as the EQ-5D-3L, valuations
of health states on a single metric are required to be able to rank
them. To do this, it must be decided whose valuations are
relevant. One approach involves asking members of the general
public to value a set of given health states (GHS) described to
them. An alternative to this method is to ask people to value only
the health state they are currently experiencing, referred to here
as experienced health states (EHS). There is no perfect distinction
between these methods, for the general public may value a
description they have experience of or have been well informedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
t the text. It is a descriptive system of health-related quality of life
ies, pain/discomfort, anxiety/depression) each of which can take
ty (no problems/some or moderate problems/extreme problems)
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and Society, Newcastle University, The Baddiley-Clark Building,
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 6 4 – 3 7 1 365about them [7]. The main difference between these methods is
that GHS valuations measure the desire for certain health states
from a societal perspective while the latter measures the hedonic
experience of a health state at an individual level [8]. Which
method is more appropriate when making resource allocation
decisions can be disputed but will depend on a number of factors,
including the context of a particular country’s health care system
and how it is funded [9]. The Washington Panel on Cost-
effectiveness in Health and Medicine has been inﬂuential with its
recommendation of using the preferences of the general popula-
tion [10], with it being included in economic guidelines in a number
of countries [3,11]. In contrast, the Swedish Dental and Pharma-
ceutical Beneﬁts Agency recommends patient-based EHS values
[12] and the German Social code focuses on patient’s beneﬁt
without mentioning the need for a societal perspective [6].
The normative debate over whose values are more appropri-
ate has been informed by empirical studies. EHS values tend to be
higher than GHS values [13–16]. Other studies, focusing on a
common generic tool the EQ-5D-3L, have found EHS values to be
lower for milder states and higher for more severe states [17,18].
Substantial variation has also been found in terms of both the
absolute and relative weight attached to the dimensions of the
EQ-5D-3L (mobility, self-care, usual activities, pain/discomfort,
and anxiety/depression) [19,20]. This study adds to the existing
literature by focusing on the practical consequences of such
differences on measuring health in a number of patient groups.
Two EQ-5D-3L tariffs were compared to analyze how they
affect mean tariff scores for different patient groups: The ﬁrst
tariff is based on EHS German valuations [18], with another
constructed using GHS valuations from across Western Europe
[21]. To give a general description of how the tariffs differ, it was
ﬁrst assessed how they vary in the relative weight assigned to the
dimensions of the EQ-5D-3L. Second, it was assessed how these
differences affect the mean tariff scores of a number of diagnosed
patient groups (those with stroke, cancer, myocardial infarction
[MI], diabetes, three comorbidity diabetes groups, and various
disease subgroups). It was seen whether the magnitude of the
difference between the tariffs was dependent on health condition
and whether these differences affected either tariff’s ability to
distinguish between groups.Methods
Selection of the EQ-5D-3L Tariffs
The tariffs were selected with the aim of isolating the effects of
using the valuations of experienced states as best as possible
while still providing robust estimates. Both the tariffs obtained
values using the visual analogue scale (VAS), which has been
criticized as a poor measure of cardinal preferences for health
states, with preference being for choice-based methods such as
the time trade-off (TTO) and the standard gamble [22]. Never-
theless, the VAS was suitable for comparison in this study
because it is more attractive when measuring the experience of
a state than are choice-based measures, which require respond-
ents to make comparisons with health states they do not
experience [23,24]. To avoid completely excluding choice-based
methods, the UK TTO tariff [25] was included in a robustness
check to provide an indication of how the included VAS tariffs
compare to it in terms of the relative weight attached to the
dimensions of the EQ-5D-3L. The use of the European tariff was
deemed preferable to a German-speciﬁc tariff because few stud-
ies had been conducted using the German tariff and those that
had been were of a small scale, which was believed may result in
underestimates of the detriments to health [26].The EHS-Based Tariff
The EHS tariff was developed by Leidl and Reitmeir [18] using the
VAS for the valuation of health states of the EQ-5D-3L. The tariff is
based on valuations from a representative German population
survey of 2032 participants conducted nationally in 2006.
Respondents in the survey were asked to value their current
health using the VAS as part of a health questionnaire. They
reported 49 EQ-5D-3L health states, with each state being valued
by varying the number of individuals, with the majority of
respondents (66.4%) reporting no problems (the EQ-5D-3L state
“11111”). A tariff of estimated scores for all the 243 states of the
EQ-5D-3L was constructed using a generalized linear model with
binomial error distributions. The tariff ranges from a score of 89.3
for the “no problems” state of the EQ-5D-3L (11111) and 18.5 for
the “severe problems” state in all dimensions (33333). Its predic-
tive ability has been tested in both patients recovering from stroke
[27] and patients with inﬂammatory bowel disease [28] and has
been found to provide good estimates of a patient’s quality of life.
Hunger et al. [27] used data collected alongside a randomized
clinical trial of education rehabilitation for patients recovering
from stroke in Bavaria that included EQ-5D-3L VAS valuations and
the Stroke Impact Scale. They found that the EHS tariff had better
correlation with the Stroke Impact Scale than did patient-reported
VAS values. Leidl et al. [28] used data on 270 patients with
inﬂammatory bowel disease and found that the EHS tariff pro-
vided the best estimates of a patient-reported VAS value when
compared with TTO tariffs for the United Kingdom and Germany.
The European GHS-Based Tariff
The GHS tariff was developed by Greiner et al. [21], with the VAS
being used to value the health states of the EQ-5D-3L. They pooled
data from 11 different data sets collected by members of the
EuroQol Group in Finland, Germany, The Netherlands, Spain,
Sweden, and the United Kingdom. The pooling of these studies
to construct a single model was possible because each of the
included studies followed the standard EuroQol valuation ques-
tionnaire in which 13 “core” states of the EQ-5D-3L were always
valued and VAS values for these states have been found to be very
similar in Western European countries [21]. Pooling the data sets
provided them with a sample of 8,709 respondents. After exclud-
ing inconsistent responses, they were left with a sample of 6,870,
who performed 82,910 valuations on a total of 44 EQ-5D-3L health
states. Unlike the EHS tariff, a multilevel (random-effects) model
was used to allow for different use in scale by respondents.
Application of the Tariffs to EQ-5D-3L Responses from the
Cooperative Health Research in the Augsburg Region Data
The population EQ-5D-3L health state descriptions were taken from
the Cooperative Health Research in the Augsburg Region (KORA) set
of population-based surveys and its subsequent follow-up studies
conducted in the Augsburg region of Southern Germany by the
Helmholtz Centre, Munich [29], speciﬁcally from the third follow-up
cross-sectional study Gesundheit (Health) Follow-up 3 (GEFU 3). The
GEFU 3 study was conducted between 2008 and 2009, with 11,287
individuals from the Augsburg region responding primarily through
a self-reported postal questionnaire. The study asked respondents
to complete only the descriptive part of the EQ-5D-3L and not the
EQ-VAS. Respondents also provided self-reported information
regarding whether they currently suffered from or had ever suffered
from a stroke, cancer, MI, or diabetes. Of the 11,287 respondents,
10,177 provided a complete EQ-5D-3L description of their health
state, with a total of 116 different states being described. Individuals
with missing EQ-5D-3L responses were excluded from the analysis
because it was not possible to attach a score for their health
state.
F
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(diabetes, stroke, cancer, and MI), three comorbidity groups
(diabetes and cancer, diabetes and stroke, and diabetes and MI),
and a group that did not suffer from the above conditions
(referred to here as “no disease”) according to their responses to
the disease questions. Further comorbidity groups were excluded
from the analysis because of the small number of respondents
contributing data. The patient groups were separated into sub-
groups dependent on the severity of their condition as measured
by available information in the data. These groups were demar-
cated using the treatment they receive in the case of the patients
with diabetes, the time since they were diagnosed in the case of
the patients with cancer, and the frequency of events in the case
of the patients with stroke and MI.
Statistical Methods
The analysis identiﬁed differences between the tariffs in terms of
the relative weight attached to the dimensions of the EQ-5D-3L
and differences in mean tariff score for each patient group. This
was undertaken in two steps:1.ig.
veComparison across the 243 states and dimensions of the EQ-
5D-3L.2. Comparison of mean tariff scores of patient groups.
The ﬁrst part of the analyses made a general assessment of
the tariffs by comparing their mean scores for the 243 health
states of the EQ-5D-3L and the relative weight assigned to each of
its ﬁve dimensions. Mean scores across the 243 states of the EQ-
5D-3L were calculated and compared, and the states with the
largest difference between the tariff scores were identiﬁed.
Because the two tariffs had been constructed using different
modeling techniques, it was not possible to simply compare the
respective coefﬁcients for each dimension. Instead, the effect of
detriments in a given dimension was approximated by looking at
how scores of health states vary. This was achieved by holding a1 – Comparison of relative weighting of the dimensions of th
-dimensional; GHS, given health states; TTO, time trade-off; Vgiven dimension constant at a given problem level for all other
combinations of the other four dimensions (81 in total). This
divided the 243 states of the EQ-5D-3L into three groups of 81 for
each dimension (“no problems,” “some problems,” and “severe
problems”). The mean of the group with no problems in the given
dimension was then subtracted from the respective means of the
two groups with problems. The differences between these means
provided the mean detriment to health that problems in a given
dimension at a given level caused. Relative weights for the
mean detriments of each dimension were then calculated using
the same method as Rand-Hendriksen et al. [20]. The mean
detriment across the ﬁve dimensions at a given problem level
was calculated. Each dimension-speciﬁc detriment was then
divided by the mean across dimensions. This gave an indication
of how important a single dimension is relative to the other four
dimensions. Should all the dimensions be considered equally
important, the weights of all dimensions would be equal to 1.
Comparison was made with the British GHS TTO tariff
modeled by Dolan [25] as a robustness check for the use of the
VAS tariffs. The relative weights assigned by the TTO tariff to the
ﬁve dimensions were calculated using the methods described
above. The use of relative weights allows for comparison despite
the VAS tariffs using a different scale to the TTO tariff because
changing the scale will not alter the relative weight attached to
each dimension.
The second part of the analysis examined whether the differ-
ences observed in the weighting of the dimensions resulted in
different effects when applied to different patient groups from
the KORA data. This was examined in three steps. First, compar-
ison was made of mean valuations of each group to determine
the magnitude of mean difference in each group. Comparison
was made using paired t tests and intraclass correlation
coefﬁcients.
Second, ordinary least squares regressions were run to deter-
mine whether differences between the tariffs varied between the
patient groups. The difference between the tariffs was taken as
the dependent variable, whereas the independent variable con-e EQ-5D-3L. EHS, experienced health states; EQ-5D, EuroQol
AS, visual analogue scale.
Table 1 – Mean tariff score and ICC by disease group.
Health state group n EHS-based mean
tariff score
GHS-based mean
tariff score
Delta ICC P*
EQ-5D-3L questionnaire states 243 51.0 36.7 14.3† 0.71 o0.0001
Disease group
No disease 7852 77.7 82.9 5.2† 0.93 o0.0001
Diabetes 744 71.3 76.4 5.2† 0.92 o0.0001
Cancer 642 72.1 76.5 4.4† 0.92 o0.0001
MI 257 71.0 76.1 5.1† 0.93 o0.0001
Stroke 219 64.1 67.3 3.2† 0.89 o0.0001
Diabetes and cancer 126 68.3 73.8 5.5† 0.92 o0.0001
Diabetes and MI 96 64.9 70.1 5.2† 0.92 o0.0001
Diabetes and stroke 60 64.2 65.9 1.7 0.93 0.1683
Disease subgroups
No diabetes 9095 76.6 81.7 5.1† 0.93 o0.0001
Diet 214 70.5 75.6 5.1† 0.93 o0.0001
Oral 578 70.8 75.9 5.1† 0.93 o0.0001
Insulin 283 64.1 68.2 4.1† 0.90 o0.0001
No cancer 9292 76.3 81.4 5.1† 0.93 o0.0001
Diagnosed 0–1 y ago 146 68.5 73.1 4.6† 0.91 o0.0001
Diagnosed 2 or more years ago 727 71.0 75.5 4.6† 0.92 o0.0001
No stroke 9781 76.3 81.5 5.2† 0.93 o0.0001
One stroke 290 63.6 67.0 3.4† 0.91 o0.0001
More than one stroke 88 57.4 57.0 0.4 0.87 0.7691
No MI 9697 76.2 81.3 5.1† 0.93 o0.0001
One MI 359 68.4 73.2 4.8† 0.92 o0.0001
Multiple MI 89 62.7 66.7 4.1† 0.92 o0.0001
EHS, experienced health states; EQ-5D-3L, EuroQol ﬁve-dimensional; GHS, given health states; ICC, intraclass correlation coefﬁcient; MI
myocardial infarction.
* Paired t test for differences.
† Statistically signiﬁcant at the 5% level.
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The reference group, the independent variable, was the “no
disease” group. For each patient subgroup, a similar regression
analysis was performed. Each patient subgroup was deﬁned as a
categorical variable, with reference groups for each disease
subgroup being individuals who did not suffer from the disease
of that subgroup.
Third, it was assessed whether any differences in mean tariff
score affected either tariff’s ability to distinguish between the
patient groups, which provided a measure of the sensitivity of the
tariffs. This was achieved by seeing whether mean tariff scores
were signiﬁcantly different across the patient groups using
conﬁdence intervals at the 95% level.
All data manipulations and statistical analyses were carried
out using SAS for Windows version 9.2 and Microsoft Excel 2010.Results
Tariff scores were lower for 213 of 243 EQ-5D-3L health states
using the GHS tariff, with a mean score of 36.7  16.7, a
maximum of 97.7, and a minimum of 3.5. The EHS tariff gave
lower scores for 30 of the 243 states, with a mean score of 51.0
 16.6, a maximum of 89, and a minimum of 18.5. On average, the
scores of the GHS tariff were 14.3 lower than the scores of the EHS
tariff. The state with the largest difference was the state 33112, in
which the GHS tariff gave a score 40.7 lower than the EHS tariff.
The state in which the EHS tariff score was at its lowest relative
to the GHS tariff score was the state 21221, where it was 16.7
lower. The ICC across all 243 states between the two tariffs
was 0.71.The relative importance of detriments in the dimension of the
EQ-5D-3L differed between the tariffs (Fig. 1). At the “some
problems” level, mobility, usual activity, and pain/discomfort
were of relatively high importance when using the EHS tariff.
The relative importance of the pain/discomfort dimension was
particularly high. The importance of the anxiety/depression and
self-care dimensions was relatively low. This was in contrast to
when the GHS VAS tariff was used, with the self-care and
anxiety/depression dimensions being of relatively high impor-
tance while usual activity was of relatively low importance. The
relative importance of the pain/discomfort dimension was also
high but to a lesser extent than when using the EHS tariff. The
GHS TTO tariff appeared similar to the GHS tariff across the
mobility, self-care, and usual activity dimensions but assigned
greater relative weight to the pain/discomfort dimension and
lesser weight to the anxiety and depression dimensions. There
were also differences at the “severe problems” level. The pain/
discomfort dimension was of even higher relative importance
and the anxiety/depression became of high importance when
using the EHS tariff. The pain/discomfort dimension was rela-
tively important using either of the GHS tariffs but the mobility
dimension was of greater importance than the anxiety/depres-
sion dimension.
Mean tariff scores for most patient groups were lower when
applying the EHS tariff rather than the GHS tariff (Table 1).
Signiﬁcant differences were observed in all but two of the groups
(“diabetes and stroke” and those who had suffered multiple
strokes). These groups contained a greater proportion of individ-
uals with problems in dimensions that the GHS tariff assigned
greater weight to such as self-care (Fig. 2). Most patient group’s
mean score did not signiﬁcantly differ from that of their reference
group, suggesting that the scores of the tariffs change in a similar
Fig. 2 – Distribution of problems across the dimensions of the EQ-5D by disease group. Percentage reporting problems includes
problems at both the moderate and severe levels. MI, myocardial infarction.
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that contained patients with stroke and those who had been
diagnosed with cancer more than 2 years ago.
The varying mean differences between the tariffs did not
make either tariff more able to distinguish between the patient
groups or severity subgroups in general (Figs. 3 and 4). All the
patient groups had lower scores compared with the “no disease”
group using either of the tariffs. Patients with diabetes treated
with insulin had signiﬁcantly lower scores than did those treated
with other treatments using either tariff. Similarly, those who
had multiple strokes were found to have a signiﬁcantly lower score
than did those who had suffered one using either of the tariffs.Table 2 – Differences between mean tariff scores by cond
Independent variable Difference between v
Intercept 5.22†
No disease (reference) 0
Diabetes 0.07
Cancer 0.84†
MI 0.10
Stroke 2.08†
Diabetes and cancer 0.23
Diabetes and MI 0.004
Diabetes and stroke 3.53†
Disease subgroups
Intercept 5.23†
No diabetes (reference) 0
Diet 0.14
Oral 0.10
Insulin 0.60
No cancer (reference) 0
Diagnosed 0–1 y ago 0.49
Diagnosed 2 or more years ago 0.49†
No stroke (reference) 0
One stroke 1.59†
More than one stroke 5.45†
No MI (reference) 0
One MI 0.01
Multiple MI 0.61
MI, myocardial infarction.
* F test for differences.
† Statistically signiﬁcant at the 5% level.Discussion
The aim of this study was to identify the effect of difference
between EHS and GHS values on mean EQ-5D-3L tariff scores of a
number of patient groups. The two compared tariffs assigned
different weights to the dimensions of the EQ-5D-3L, and these
differences varied depending on the severity of problems. Use of
the KORA data provided descriptions of health states for a
population sample of patients suffering from various chronic
diseases. Surprisingly, it was found that the EHS tariff actually
assigned a signiﬁcantly lower mean score for most patient groupsition with reference to a given group.
aluations Standard error P*
0.067 o0.0001
0.229 0.752
0.245 0.001
0.378 0.803
0.409 o0.0001
0.536 0.675
0.613 0.995
0.773 o0.0001
0.066 o0.0001
0.413 0.736
0.258 0.710
0.368 0.104
0.499 0.332
0.230 0.032
0.359 o0.0001
0.639 o0.0001
0.323 0.978
0.646 0.349
Fig. 3 – Sensitivity of the GHS-based tariff to the included patient groups. Unadjusted mean valuations with 95% conﬁdence
intervals. Numbers in brackets are the number of individuals in each group. GHS, given health states; MI, myocardial
infarction.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 6 4 – 3 7 1 369despite the GHS tariff assigning lower scores for most of the EQ-5D-
3L states. This apparent inconsistency can be explained by the
kinds of problems that are reported by a patient group and the
difference between the scores for the “no problem” state (11111).
A relatively great weight was assigned to “some” problems in
mobility, usual activities, and pain/discomfort when using the
EHS tariff, which partly explains it having lower mean scores for
most of the patient groups. Problems at this level in these
dimensions were fairly common in many of the patient groups.
For example, in all the patient groups considered, between 46%
and 67% of all states reported contained some problems in pain/
discomfort, between 14% and 64% contained some problems in
mobility, and between 11% and 38% contained some problemsFig. 4 – Sensitivity of the EHS-based tariff to the included patien
intervals. Numbers in brackets are the number of individuals in
infarction.with usual activities. In contrast, some problems in self-care were
not so commonly reported (between 3% and 25%). When states
with severe problems were reported, they often occurred in the
pain/discomfort dimension (between 50% and 77%). This resulted
in the EHS tariff being relatively more responsive, to the problems
reported by many of the patient groups, than the GHS tariffs. In
addition, the “no problem” state was the most frequently
reported state in many of the groups (between 8% and 44% of
all reported states). Because the EHS tariff has a score 8.3 lower
for the “no problem” state (11111), it plays a role in it having
lower mean tariff scores for most of the patient groups.
The difference between the tariff scores varied across the
patient groups as a result of changes in problems reported. Meant groups. Unadjusted mean valuations with 95% conﬁdence
each group. EHS, experienced health states; MI, myocardial
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 6 4 – 3 7 1370scores of groups containing patients with stroke were found to be
more responsive when using the GHS tariffs. The largest change
in difference was 5.45 in the group of patients who had suffered
multiple strokes. A change of this magnitude was not found to
make the GHS tariff more able to distinguish those who had
multiple strokes from those who had suffered a single stroke.
This would suggest that the variation in the weighting of the
dimensions does not necessarily result in large variations in
mean tariff scores. Analysis with a larger number of patient
groups is required to assess whether larger differences occur
when other health states are reported. The analysis would have
beneﬁted from a wider range of conditions than the chronic
states contained in the KORA data.
When the results of this study are compared with the results
of other studies, which have made comparisons between meth-
ods of scoring the EQ-5D-3L, similar patterns of relative weights
were observed using GHS tariffs but EHS tariffs appear to vary.
This study found the pain/discomfort dimension to be of greatest
relative importance when using the EHS tariff. In contrast, Mann
et al. [19] found EHS valuations of those experiencing a range of
health conditions to attach greater relative importance to the
anxious/depressed dimension while pain/discomfort problems
were of relatively low importance. The results of Rand-
Hendriksen et al. [20] differed from results of both this study
and those of Mann el al. [19]. They found EHS values from a US
population survey to attach greater relative importance to the
usual activities dimension [20]. These seemingly contradictory
ﬁndings could result from differences in modeling, differences in
populations providing the valuations, or differences in the way
valuations were collected. Disentangling these differences would
require comparative reanalysis of these studies’ data using
standardized valuation and modeling techniques. Thus, further
evidence is required to assess how these issues affect the
relationship between EHS and GHS tariffs.
The results of the analysis have several limitations. First,
comparison in terms of conventional quality-adjusted life-years
is not possible because it is not possible to use the conventional
quality-adjusted life-year scale, where perfect health, as
described by the “no problems” state of the EQ-5D-3L (11111), is
assigned a value of 1 and death a value of 0. VAS values on a scale
of 0 to 100 can be transformed to this scale using a mean value of
the “no problems” state and a mean value for death [30]. This was
possible with the GHS tariff, which values both the “no problems”
state and death, but not for the EHS tariff, which does not include
death as a health state. Alternatively, it would have been possible
to use the GHS tariff’s valuation of death to rescale the EHS tariff
but given that a value of death cannot be experienced in nature, it
was deemed inappropriate to incorporate GHS valuations into the
EHS tariff. In addition, it is debatable whether it is appropriate to
ask respondents to value death [31]. The analysis was also
limited by a lack of data on how an individual’s health state
changed over time. The analysis would have beneﬁted from being
able to assess how differences between the tariffs result in
changes in health being assigned varying scores.Conclusions
This study has provided evidence of how the discrepancy
between patient and general population values translates into
systematic differences in mean tariff scores of different patient
groups. It was found that discrepancies may not always translate
into large differences in mean tariff score. This will be dependent
on what kinds of problems are reported by a speciﬁc patient
group. Larger differences could be observed given that very
large differences exist between individual health states. Thus,
the systematic differences between the methods in certaincircumstances could drive results of an economic evaluation.
Therefore, the choice as to which valuation method is used for a
given patient group may be critical in resource allocation decisions.Acknowledgments
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